GlobalData on MSN12h
FDA beats EMA to most approved new drugs in 2024
The FDA has narrowly beaten the European Medicines Agency (EMA) to the most approved drugs with a new active substance in ...
Le Lézard11h
Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia
Zai Lab Limited today announced that China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for KarXT for the treatment of schizophrenia in adults. "There ...
Hosted on MSN24m
Bristol Myers Squibb (BMY) Stock Dips While Market Gains: Key Facts
Bristol Myers Squibb (BMY) ended the recent trading session at $56.29, demonstrating a -0.16% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain ...
bovnews11h
Bristol-Myers Squibb Co (BMY) Stock Posted a Gross Margin of 55.87% Over the Past Year: Is This Justifiable?
Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the ...
Chinese regulators accept Zai Lab application for KarXT
Chinese regulators have accepted Zai Lab's (NASDAQ:ZLAB) market application for the drug KarXT, also known as xanomeline and ...